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Millions of children require surgical procedures and anaesthesia every year around the world. Children who undergo anaesthesia and surgery may have increased risk of cognitive deficiency and changes in brain structure (e.g. reduced grey matter density in both occipital cortex and cerebellum, [1] [2] [3] reviewed by Sun 4 and
Vutskits and Xie 5 ). Wilder and colleagues 1 reported that children <4 yr old who received multiple (e.g. three times), but not single, episodes of anaesthesia and surgery had increased risk of learning disability before the age of 15 yr. Recent prospective epidemiological studies show that single and short-duration anaesthesia (e.g. sevoflurane) and surgery (e.g. hernia repair) are not associated with cognitive deficiency in children. 6 7 However, several other studies have shown an association between cognitive deficiency and surgery under anaesthesia in children. 2 3 8-11 Anaesthesia can induce cognitive deficiency and neurotoxicity in young rodents [12] [13] [14] [15] [16] and monkeys. [17] [18] [19] [20] [21] Mitochondrial dysfunction might contribute to this anaesthetic neurotoxicity. Anaesthesia with midazolam, nitrous oxide, and isoflurane enlarged mitochondrial size, impaired structural integrity of mitochondria, and increased complex IV activity. 22 The same combination of anaesthetics increased brain concentrations of reactive oxygen species (ROS) and impaired the balance between mitochondrial fission and fusion, which caused excessive fission and impaired mitochondrial morphogenesis. 23 The NADPH oxidase inhibitor apocynin attenuated sevofluraneinduced cognitive impairment and the increase in brain concentrations of superoxide and NADPH oxidase subunit p22phox. 24 Multiple exposures to sevoflurane anaesthesia in young rats caused mitochondrial toxicity and reduced the number of synapses in rat hippocampus. 25 Moreover, treatment with the ROS scavenger EUK-134 and restoration of mitochondrial integrity by R(þ) pramipexole inhibited the anaesthesia-induced mitochondrial dysfunction and cognitive impairment in rats. 26 Our previous experiments showed that anaesthesia can produce mitochondrial dysfunction and suggested the involvement of energy deficiency in anaesthetic neurotoxicity. 27 Mitochondrial dysfunction induced by isoflurane contributes to isofluraneinduced apoptosis, 28 29 which might accelerate the neuropathogenesis of Alzheimer's disease (reviewed by Vutskits and Xie 5 ). Moreover, mitochondrial dysfunction can impair synapse formation. 30 A recent study showed that multiple exposures to sevoflurane in monkeys can induce synaptic loss and mitochondrial dysfunction, and there was a positive association between mean presynaptic mitochondrial density and mean synaptic density after sevoflurane anaesthesia. 25 These findings suggest a connection between synaptic loss and mitochondrial dysfunction.
However, it remains largely unknown how anaesthesia can induce mitochondrial dysfunction leading to cognitive impairment (e.g. the duration and timing of anaesthesia). The impact of anaesthesia on synaptogenesis or synapse maintenance in developing brain and potential treatments remain to be determined. The goal of the present proof-of-concept research was to determine whether an energy enhancer could alleviate anaesthesiainduced cognitive deficiency and reduce the anaesthesia-induced reduction in brain concentrations of synaptic markers, adenosine triphosphate (ATP), and mitochondrial function indicators [ROS and mitochondrial membrane potential (MMP)] in young mice. Coenzyme Q 10 (CoQ 10 ; ubiquinone) is an endogenous lipid-soluble antioxidant found mainly in the mitochondrial inner membrane. 31 Coenzyme Q 10 is a significant cofactor in the electron transport chain of mitochondria and has neuroprotective, energyconverting, anti-inflammatory, and antioxidant effects. [32] [33] [34] [35] Specifically, CoQ 10 can improve bioenergetic functions of mitochondria, enhance brain energy levels (e.g. increase ATP), and improve brain function in rodents. 36 37 Finally, CoQ 10 reduces ROS and mitochondria dysfunction [36] [37] [38] and reduces amyloidassociated pathology in Alzheimer's disease transgenic mice. 39 40 However, the interaction of CoQ 10 and anaesthesia on cognitive function in young mice has not been determined. We therefore assessed whether CoQ 10 mitigates sevoflurane-induced cognitive deficiency and probed the underlying mechanisms. This included measurement of the effects of sevoflurane on the concentrations of synaptic markers, specifically synaptophysin, 41 42 a presynaptic marker, and postsynaptic density protein-95 (PSD-95), [43] [44] [45] [46] [47] [48] an excitatory postsynaptic marker. Our previous studies have shown that sevoflurane anaesthesia reduces PSD-95 in the young mouse hippocampus. 16 Sevoflurane anaesthesia in pregnant mice also reduces amounts of both PSD-95 and synaptophysin in fetal mouse brain. 49 We tested the hypothesis that CoQ 10 reduces sevofluraneinduced cognitive deficiency and alleviates sevoflurane-induced reductions in PSD-95, synaptophysin, ROS, MMP, and ATP in young mouse hippocampus and cortex.
Methods

Anaesthesia and treatment of mice
We completed all tests according to the guidelines and regulations of National Institutes of Health (NIH). The Standing Committee on the Use of Animals in Research and Teaching at Massachusetts General Hospital approved the study, including the care of animals (protocol number: 2006N000219, Boston, MA, USA). We minimized the number of mice used in the tests. We used both female and male mice (C57BL/6J; Jackson Laboratories, Bar Harbor, ME, USA) but did not assess potential sex differences in the present studies. A total of 134 young mice were assigned randomly into the following four groups: control plus corn oil; control plus CoQ 10 ; sevoflurane plus corn oil; and sevoflurane plus CoQ 10 . The mice were placed in an anaesthesia chamber to receive the anaesthesia or control using 3% sevoflurane plus 60% oxygen (balanced with nitrogen) for 2 h daily for 3 days from postanatal day (P) 6 to P8 as performed in our previous studies. 15 16 The sevoflurane concentration of 3% is a clinically relevant concentration, and anaesthesia for 2 h daily for 3 days from P6 to P8 conceptually mimics multiple exposures of anaesthesia in young patients. The control condition was oxygen (60% oxygen, balanced with nitrogen) with an equal rate of flow in a chamber similar to the anaesthesia chamber. 15 16 Mice in the control conditions were separated from the dams and given the control gas (60% oxygen)
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exposures (Fig. 1) . Specifically, 24 mice were decapitated at the end of the anaesthesia at P8 for harvest of the hippocampus, which was used in the western blot studies. Thirty-six mice were decapitated at the end of the anaesthesia at P8 for harvest of the cortex for ATP measurement. Twenty-four mice were decapitated at the end of anaesthesia at P8 for harvest of the hippocampus and cortex for measurement of ROS (hippocampus) and MMP (mitochondria from cortex). Fifty mice were used for Morris water maze (MWM) from P31 to P37 and western blot studies at P37. The anaesthesia chamber size was 20 cm (length) Â 20 cm (width) Â 7 cm (height). The induction fresh gas flow rate was 2 litres min À1 for 3 min (for the purpose of induction) and then 1 litre min À1 (for maintenance). The anaesthetic and oxygen were continuously sampled from the distal portion of the cylindrical chamber using a gas analyser (Dash 4000; GE Healthcare, Milwaukee, WI, USA) during anaesthesia. We monitored and controlled the anaesthesia chamber temperature via a feedbackbased system (DC Temperature Control System; World Precision Instruments, Inc., Sarasota, FL, USA) to control rectal temperature at 37 C (0.5 C) by placing a warming pad under the chamber. Previous studies 14 50 have shown that anaesthesia with 3% sevoflurane did not significantly modify pH values, oxygen partial pressure, or carbon dioxide partial pressure in young mice. We therefore did not measure blood gases in the present studies.
We assessed food and water consumption by the quantity of food and water used and by variations in mouse weight during the study. In the intervention studies, we gave CoQ 10 (50 mg kg
À1
, dissolved in corn oil at a concentration of 1.5 mg ml
(Sigma-Aldrich, Inc., St Louis, MO, USA) 51 by intraperitoneal (i.p.) administration 30 min before sevoflurane anaesthesia on P6, P7, and P8. Mice in the control group received 100 ml corn oil i.p.
Morris water maze experiments
We performed MWM experiments using published protocols. 15 We tested P31 mice in the MWM for 7 days (from P31 to P37) with four tests daily. We used a video recording device to track mice swimming in the pool. Both escape latency (time to reach the platform) and platform crossing (times the mouse moved across the original area of the removed platform) were recorded on P37 to assess spatial learning and memory capacities. We maintained mouse body temperature using a heating device as described 15 16 52 by placing each mouse under a heat lamp for 5 min in a holding cage to dry the mouse. We then returned the mouse to its home cage.
Harvest of brain tissue and quantification of proteins
Mice were allowed to totally recover from anaesthesia. We killed mice by decapitation one hour after the end of sevoflurane anaesthesia on P8 or P37, and harvested the hippocampus and cerebral cortex for analysis of synaptic proteins, ROS, MMP and ATP. We homogenized the harvested hippocampus or cortex on ice in immunoprecipitation buffer (Tris-HCl: 10 mM, pH 7.4; NaCl: 150 mM; EDTA: 2 mM, Nonidet P-40: 0.5%) plus protease inhibitors (aprotinin: 1 lg ml
À1
; leupeptin: 1 lg ml
, pepstatin A: 1 lg ml À1 ). Lysates were centrifuged for 10 min at 14800g. Total protein was quantified using a bicinchoninic acid protein assay kit (Pierce, Iselin, NJ, USA).
27
Western blot analysis
We used PSD-95 antibody (Cell Signaling, Danvers, MA, USA; #2507) at 1:1000 dilution, synaptophysin antibody (Cell Signaling; #4329) at 1:1000 dilution, and a b-actin antibody (Sigma, St Louis, MO, USA; #A5441) at 1:5000 dilution for quantification by western blot analysis as described by Zhang and colleagues. 27 We analysed the signal intensity using the Quantity One image analysis program (Bio-Rad, Hercules, CA, USA). We used b-actin concentrations to standardize amounts of protein (e.g. calculating the proportion of PSD-95 in relationship to the quantity of b-actin) and limit disparities in the quantity of protein loaded. We expressed the protein concentrations as a percentage in relationship to control mice.
Measurement of ATP
We used another cohort of mice for ATP measurement performed using the ATP Colorimetric/Fluorometric Assay Kit (BioVision, Milpitas, CA, USA). [53] [54] [55] [56] We homogenized cerebral cortex on ice using 100 ml ATP assay buffer. We then we took 80 ml of sample and 20 ml ice-cold perchloric acid and put them Young mice (n¼134) received anaesthesia with 3% sevoflurane for 2 h or control on 3 days at postnatal day (P) 6, P7, and P8. We harvested brain tissue (hippocampus and cortex) at the end of anaesthesia on P8 for western blotting (n¼24), measurement of adenosine triphosphate (ATP; n¼36), and measurement of reactive oxygen species (ROS) and mitochondrial membrane potential (MMP; n¼24). Different groups of mice (n¼50) were used for assessment of learning and memory function using the Morris water maze from P31 to P37 after the birth. We harvested hippocampus at the end of the Morris water maze assessments (P37) for western blotting (n¼50).
on ice for 5 min with vortexing. We centrifuged the samples for 2 min at 13 000g. The supernatant (76 ml) was transferred to a new tube, and 4 ml ice-cold neutralization solution was added, mixed to neutralize the sample, placed on ice, and opened to the air for 5 min. We then centrifuged the tube at 13 000g for 2 min for the bicinchoninic acid assay. We added sample and ATP assay buffer (1 mM) to 50 ml per well in a 96-well plate, and added reaction mix of 50 ml to each well containing the ATP standard or test samples. The reaction mix included 44 ml ATP assay buffer, 2 ml ATP probe, 2 ml ATP converter, and 2 ml developer, and samples were incubated for 30 min at room temperature (avoiding light). We measured the absorbance (optical density at 570 nm) in a microplate reader to calculate the concentration of ATP.
Measurement of ROS
An OxiSelect In Vitro ROS/RNS Assay Kit (Cell Biolabs, San Diego, CA, USA) was used to measure ROS in vivo according to protocols provided by company and used in previous studies. 57 58 Specifically, the harvested brain tissues (hippocampus) were homogenized on ice using 1% Triton-100 in phosphate-buffered saline plus protease inhibitors (1 lg ml À1 aprotinin, 1 lg ml À1 leupeptin, and 1 lg ml À1 pepstatin A). Lysates were collected, centrifuged at 10 300g for 5 min, and quantified for total protein by bicinchoninic acid protein assay. We added 50 ll of each sample (triplicate) to a black 96-well plate and 50 ll of catalyst solution, and then incubated the mixture for 5 min at room temperature. We then added 100 ll of dichlorodihydrofluorescin (DCFH) solution included in the kit to the samples, and incubated the mixture at room temperature for 20 min away from light. Fluorescence was read with a fluorometric plate reader at excitation 480 nm, emission 530 nm.
Isolation of mitochondria and determination of mitochondrial membrane potential
We used a mitochondrial isolation kit (Thermo Fisher Scientific, Waltham, MA, USA) to isolate mitochondria from brain to detect MMP as described. 28 59 Specifically, cerebral cortex was placed in a 2 ml microcentrifuge tube and cut into small pieces in 800 ll of phosphate-buffered saline. Tubes were centrifuged at 1000g for 3 min, and the supernatant was removed and discarded. Then we added 800 ll of mitochondrial isolation reagent A into each of the tubes, and the tubes were vortexed for 5 s and incubated on ice for 5 min. We added 10 ll of mitochondrial isolation reagent B into each of the tubes, and each tube was vortexed for 5 s and incubated on ice for 5 min before adding 800 ll of mitochondrial isolation reagent C. Tubes were centrifuged at 700g for 10 min at 4 C, and the supernatant was transferred to a new 1.5 ml tube and centrifuged at 3000g for 15 min. We collected the pellet, which contained isolated mitochondria. Protein concentrations in the mitochondrial pellets were measured using the bicinchoninic acid protein assay. Freshly isolated mitochondria were used immediately for determination of MMP. We used a JC-1 (5,50,6,60-tetrachloro-1,10,3,30 tetraethylbenzimidazolylcarbocyanine iodide) mitochondrial membrane potential detection kit (Biotium, Hayword, CA, USA) to determine MMP according to the manufacturer's protocol as described by Baumber and colleagues. 60 The MMP was calculated by detection of the JC-1 fluorescence ratio. Specifically, isolated mitochondria were resuspended in 0.5 ml 1Â JC-1 reagent, incubated at 37 C in a 5% CO 2 incubator for 15 min, centrifuged for 5 min at 400g, and the pellet was resuspended in 2 ml 1Â assay buffer followed by centrifugation. We resuspended the pellet in 0.3 ml 1Â assay buffer and measured red (excitation 550 nm, emission 600 nm) and green (excitation 485 nm, emission 535 nm) fluorescence using a fluorescence plate reader. The ratio of red to green fluorescence is decreased in dead samples and in samples undergoing apoptosis compared with healthy samples.
Statistics
We expressed data obtained from biochemistry studies and MWM escape latency as the means (SD). Numbers of platform crossing of MWM were not normally distributed, and they are expressed as medians with the interquartile range. The number of samples was 10-16 per group in behavioural studies and six to nine per group in biochemistry studies. These numbers were selected according to the results obtained in our previous studies. We used two-way ANOVA (repeated measurements) to evaluate the difference of escape latency of mice in the anaesthesia cohort compared with the control cohort in the MWM. We used post hoc analysis to contrast the change in escape latency for each day during the MWM test, and cut-off a was Bonferroni adjusted. We used the Mann-Whitney U-test to compare the platform-crossing times of mice in the anaesthesia cohort with mice in the control cohort. We used two-way ANOVA to evaluate the interaction of group (control vs anaesthesia) and treatment (CoQ 10 vs corn oil) on the amounts of PSD-95, synaptophysin, ATP, ROS, and MMP. Two-tailed hypothesis testing was used. Statistical significance was defined as P<0.05. We used Prism 6 (GraphPad, La Jolla, CA, USA) to evaluate all data.
Results
Coenzyme Q 10 treatment reduced sevoflurane-induced cognitive deficiency
We determined whether CoQ 10 , a mitochondrial energy enhancer, 36 37 could reduce the anaesthesia-induced cognitive deficiency in young mice. In mice pretreated with corn oil (vehicle), anaesthesia with sevoflurane (3% sevoflurane 2 h daily for three days) on P6, P7, and P8 induced cognitive deficiency in the MWM test from P31 to P37. There was a borderline significant interaction (F¼2.17, P¼0.05, two-way ANOVA) between the group (control vs anaesthesia) and time (P31-P37). Sevoflurane anaesthesia increased the time (escape latency) for mice to locate the platform in the MWM pool compared with the control conditions ( Fig. 2A) . Post hoc testing (Bonferroni) showed that the anaesthesia mice took longer (escape latency) to locate the platform compared with control mice at P35 (P<0.01) and P37 (P<0.05; Fig. 2A ). Sevoflurane anaesthesia also reduced platform-crossing times compared with control conditions (Fig. 2B ; P¼0.01, Mann-Whitney U-test).
In mice pretreated with CoQ 10 , sevoflurane anaesthesia did not induce cognitive deficiency tested with the MWM. No significant interaction (F¼0.90, P¼0.49) between group (control and anaesthesia) and time (P31-P37) was observed, and sevoflurane anaesthesia did not significantly increase the time (escape latency) for mice to locate the platform (Fig. 2C) . Sevoflurane anaesthesia did not decrease platform-crossing times compared the control conditions ( Fig. 2D; P¼0 .78, Mann-Whitney U-test).
Coenzyme Q 10 reduced sevoflurane-induced reductions in PSD-95 and synaptophysin in hippocampus Given that CoQ 10 alleviated sevoflurane-induced cognitive deficiency, we inquired whether CoQ 10 could reduce sevoflurane-induced changes in synaptic markers. Synaptophysin 41 42 and PSD-95 [43] [44] [45] [46] [47] [48] are pre-and postsynaptic markers, respectively. Sevoflurane has been reported to reduce amounts of PSD-95 in young mouse hippocampus 16 52 and to reduce amounts of PSD-95 and synaptophysin in fetal mouse brain. 49 We investigated the effects of CoQ 10 on the amounts of PSD-95 and synaptophysin in hippocampus of the young mice after sevoflurane anaesthesia. Immunoblotting analysis showed that sevoflurane anaesthesia (Fig. 3A) reduced amounts of PSD-95 in hippocampus compared with control conditions at P8. Coenzyme Q 10 ( Fig. 3A) itself did not significantly modify amounts of PSD-95 compared with vehicle. However, CoQ 10 attenuated sevoflurane-induced reductions in amounts of PSD-95 (Fig. 3A) at P8. Western blot quantification showed that sevoflurane (Fig. 3B ) reduced amounts of PSD-95 compared with control conditions, and CoQ 10 attenuated the reduction in PSD-95 induced by sevoflurane anaesthesia at P8 (F¼10.56, P<0.01, two-way ANOVA). We also found that sevoflurane anaesthesia ( Fig. 3C and D) decreased PSD-95 in hippocampus compared with control conditions at P37. Coenzyme Q 10 ( Fig. 3C and D) itself did not significantly modify amounts of PSD-95 compared with vehicle. However, CoQ 10 attenuated the sevoflurane-induced reduction in amounts of PSD-95 at P37 (F¼10.88, P<0.01, two-way ANOVA; Fig. 3C and D) . Sevoflurane anaesthesia also reduced synaptophysin concentrations in hippocampus compared with control conditions (Fig. 4A and B) at P8. Coenzyme Q 10 attenuated sevoflurane-induced reduction in amounts of synaptophysin at P8 ( Fig. 4A and B ; F¼8.44, P¼0.01, two-way ANOVA). Finally, sevoflurane anaesthesia decreased synaptophysin concentrations in hippocampus compared with control conditions at P37 (Fig. 4C  and D) , and CoQ 10 attenuated sevoflurane-induced reductions in amounts of synaptophysin at P37 (F¼24.78, P<0.01, two-way ANOVA; Fig. 4C and D) . Collectively, these data show that CoQ 10 attenuates both the cognitive deficiency in young mice from P31 to P37 and the reduction in amounts of PSD-95 and synaptophysin (synaptic markers) in hippocampus at P8 and P37 induced by sevoflurane anaesthesia.
Coenzyme Q 10 reduced sevoflurane-induced reductions in ATP in cerebral cortex
Next, we determined the effects of CoQ 10 on sevofluraneinduced changes in ATP mouse cerebral cortex. Two-way ANOVA presented a borderline significant interaction of group (control vs anaesthesia) and treatment (corn oil vs CoQ 10 ) on amounts of ATP (F¼4.343, P¼0.05; Fig. 5 ). Specifically, sevoflurane anaesthesia decreased amounts of ATP in cortex compared with control conditions (Fig. 5) . Coenzyme Q 10 attenuated the sevofluraneinduced reductions in amounts of ATP (Fig. 5) . Collectively, these data further suggest that CoQ 10 reduced the cognitive deficiency and attenuated reductions in PSD-95, synaptophysin, and ATP induced by sevoflurane anaesthesia. 
Coenzyme Q 10 did not reduce sevoflurane-induced increases in ROS in hippocampus
Given the findings that CoQ 10 attenuated the sevoflurane-induced reduction in amounts of ATP, we asked whether CoQ 10 could reduce sevoflurane-induced changes in mitochondrial function. Sevoflurane anaesthesia increased ROS compared with control conditions (Fig. 6 ) in hippocampus at P8. However, CoQ 10 did not attenuate the sevoflurane-induced increase in the amount of ROS (F¼1.72, P¼0.20, two-way ANOVA; Fig. 6 ).
Coenzyme Q 10 reduced sevoflurane-induced reduction in MMP in cerebral cortex
Finally, we found that sevoflurane anaesthesia decreased the MMP in mitochondria from the cerebral cortex of the mice at P8 compared with control mice (Fig. 7) . Moreover, two-way ANOVA showed a significant interaction between group (control vs sevoflurane) and treatment (corn oil vs CoQ 10 ), and CoQ 10 attenuated sevoflurane-induced reductions in MMP concentrations in cortex at P8 (F¼11.43, P<0.01; Fig. 7 ). Collectively, these data suggest that sevoflurane anaesthesia decreases brain ATP concentrations in young mice by impairing mitochondrial function, and CoQ 10 can mitigate the sevoflurane-induced reduction in ATP by attenuating the sevoflurane-induced reduction in brain MMP, but not the sevoflurane-induced increase in brain ROS at P8.
Discussion
In this proof-of-concept study, we assessed whether CoQ 10 could lessen the sevoflurane-induced cognitive deficiency in young mice and inhibit sevoflurane-induced changes in synaptophysin, PSD-95, ATP, ROS, and MMP in hippocampus and cerebral cortex. We found that sevoflurane anaesthesia caused cognitive deficiency in young mice, consistent with our previous studies. 15 16 However, in young mice pretreated with CoQ 10 , sevoflurane anaesthesia did not induce cognitive deficiency. Given that CoQ 10 is a brain energy enhancer, 36 37 these data suggest that brain energy deficits could contribute, at least in part, to the cognitive deficiency induced by sevoflurane anaesthesia, and CoQ 10 could be used to prevent or treat the anaesthesiainduced cognitive deficiency in young mice. Coenzyme Q 10 also attenuated sevoflurane-induced reductions in the amounts of PSD-95 and synaptophysin, which are postsynaptic 41 42 and presynaptic markers, [43] [44] [45] [46] [47] [48] respectively. These data suggest that the underlying mechanisms by which CoQ 10 reduces sevoflurane-induced cognitive deficiency include rescue of sevoflurane-induced synaptic dysfunction in the hippocampus.
Coenzyme Q 10 also attenuated sevoflurane-anaesthesia-induced decreases in ATP concentrations in cerebral cortex. Collectively, these results that CoQ 10 reduced sevofluraneinduced cognitive deficiency and reductions in synaptic markers and energy levels in young mouse brain support the hypothesis that brain energy deficits contribute to the anaesthesia-induced cognitive deficiency. Pending further investigation, these findings demonstrate the potential underlying mechanisms of anaesthesia-induced neurobehavioural deficits and neurotoxicity in the developing brain and suggest that energy enhancers, including CoQ 10 and vitamin K 2 , 61 might be used to mitigate potential postoperative cognitive decline or dysfunction in children. Coenzyme Q 10 has been reported to augment brain energy levels and enhance cognitive function in rodents. For example, CoQ 10 was able to reduce the brain energy deficit and cognitive dysfunction trigged by intracerebroventricular streptozotocin in rats. 62 Coenzyme Q 10 improved cognitive function in Alzheimer's disease transgenic mice, 63 and age-associated deficiency 64 and cognitive deficiency 65 in mice. Finally, CoQ 10 reduced b-amyloidinduced cognitive deficiency in mice. 66 We show, for the first time, that CoQ 10 can reduce anaesthesia-induced cognitive deficiency and rescue anaesthesia-induced brain energy deficits in mice. We postulated that anaesthesia might cause neurotoxicity and neurobehavioural deficits in young mice by producing brain energy deficits. Further investigations are warranted to test this hypothesis. Activity-driven ATP synthesis is required for synaptic function, and a reduction in activity-stimulated ATP synthesis leads to deficiency of presynaptic function. 67 We found CoQ 10 reduced sevoflurane-induced reductions in both synaptic markers and the concentration of ATP in brain. Thus, it is conceivable that sevoflurane anaesthesia reduces brain energy levels, which then causes synaptic dysfunction, leading to cognitive deficiency. Moreover, we found that sevoflurane anaesthesia increased ROS concentrations and decreased MMP, but CoQ 10 rescued only the sevoflurane-induced reduction in MMP. These data suggest that CoQ 10 Several studies have demonstrated that anaesthetics can cause mitochondrial dysfunction, including enlargement of the size of mitochondria, impairment of structural integrity of mitochondria, increased complex IV activity, increased amounts of ROS, impaired balance between mitochondrial fission and fusion, and reductions in the fraction of presynaptic terminals containing mitochondria in brain tissues of rodents. 22 23 25 Moreover, the NADPH oxidase inhibitor apocynin, ROS scavenger EUK-134, and R(þ) pramipexole (which can recover mitochondrial integrity) can mitigate anaesthesia-induced mitochondrial dysfunction and cognitive impairment. 24 26 Our findings that CoQ 10 ameliorated sevoflurane-induced cognitive impairment in young mice and reductions in brain concentrations of synaptic markers, ATP, and MMP suggest that CoQ 10 prevents or treats anaesthesia-induced cognitive impairment by rescuing mitochondrial dysfunction in the mice. These findings also provide an opportunity to design new interventions to prevent or treat possible anaesthesia-induced cognitive deficiency in children. Multiple exposures to sevoflurane anaesthesia in young rats caused synaptic loss in rat hippocampus, 25 and isoflurane anaesthesia in young rats caused a reduction in synaptic density in the hippocampus. 68 Anaesthesia with midazolam, nitrous oxide, and isoflurane reduced synapse volumetric densities in the hippocampus of young rats, 69 and sevoflurane decreased the synaptic marker PSD-95 in the hippocampus of young mice. 16 52 However, the upstream mechanism by which anaesthetic reduces concentrations of synaptic markers and synaptic function remains largely to be investigated. Our studies have several limitations. First, we used only one energy enhancer (CoQ 10 ). It is unknown whether other energy enhancers, such as vitamin K 2 , 61 can also rescue the anaesthesia-induced energy deficits and synaptic dysfunction and reduce the anaesthesia-induced cognitive deficiency. Second, we assessed the concentrations of ATP and MMP in the cortex, but not the hippocampus, of young mice because of an insufficient amount of hippocampus for measurement of ATP and for the harvest of mitochondria (for the MMP measurement). In future studies, we need to develop better methods to detect the effects of the sevoflurane anaesthesia on ATP and MMP in hippocampus of young mice.
In conclusion, in this proof-of-concept study, we demonstrated that CoQ 10 , an energy enhancer, reduced sevofluraneinduced cognitive deficiency and rescued sevoflurane-induced reduction in the synaptic markers MMP and ATP in young mouse hippocampus. These results imply that anaesthesia causes brain energy deficits by impairing mitochondrial function, which induces synaptic dysfunction, finally leading to cognitive deficiency in young mice. These discoveries provide the basis for more research to examine the underlying mechanisms and targeted interventions for potential cognitive dysfunction after anaesthesia and surgery in children.
